Genmab reported DKK2.66B in Operating Profit for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Agios Pharmaceuticals AGIO:US USD 28.68M 115.33M
Amarin AMRN:US USD -5144000 57.69M
Amgen AMGN:US USD 2.23B 508M
Artemis Alpha ATS:LN GBP -26696000 16.49M
AstraZeneca AZN:LN USD 1.09B 151M
Bayer BAYN:GR EUR 1.43B 233M
Biomarin Pharmaceutical BMRN:US USD -24500000 22.08M
Bluebird Bio BLUE:US USD -84781000 22.62M
Exelixis EXEL:US USD -48078000 130.69M
Fresenius Medical Care FME:GR EUR 352M 119.64M
Genmab GEN:DC DKK 2.66B 734M
GlaxoSmithKline GSK:LN GBP 1.87B 677M
GN Store Nord GN:DC DKK 438M 74M
Hikma Pharmaceutical HIK:LN USD 60M 189M
Immunogen IMGN:US USD -59559000 17.87M
Insmed INSM:US USD -151475000 23.78M
Merck MRK:GR EUR 889M 345M
Novartis NOVN:VX USD 1.95B 219M
Regeneron Pharmaceuticals REGN:US USD 1.15B 76.9M
Roche Holding ROG:VX 5.93B 5.62B
Seattle Genetics SGEN:US USD -154004000 38.8M
William Demant Holding WDH:DC DKK 1.62B 31M